Bonesupport Holding Dirección

Dirección controles de criterios 3/4

El CEO de Bonesupport Holding es Emil Billbäck , nombrado en Mar 2018, tiene una permanencia de 6.67 años. compensación anual total es SEK15.18M, compuesta por 41.7% salario y 58.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.33% de las acciones de la empresa, por valor de SEK81.04M. La antigüedad media del equipo directivo y de la junta directiva es de 5 años y 7.8 años, respectivamente.

Información clave

Emil Billbäck

Chief Executive Officer (CEO)

SEK 15.2m

Compensación total

Porcentaje del salario del CEO	41.7%
Permanencia del CEO	6.7yrs
Participación del CEO	0.3%
Permanencia media de la dirección	5yrs
Promedio de permanencia en la Junta Directiva	7.8yrs

Actualizaciones recientes de la dirección

Recent updates

Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

Oct 31

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

Mar 16

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Nov 06

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Emil Billbäck en comparación con los beneficios de Bonesupport Holding?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	SEK 91m
Jun 30 2024	n/a	n/a	SEK 289m
Mar 31 2024	n/a	n/a	SEK 267m
Dec 31 2023	SEK 15m	SEK 6m	SEK 245m
Sep 30 2023	n/a	n/a	SEK 214m
Jun 30 2023	n/a	n/a	-SEK 30m
Mar 31 2023	n/a	n/a	-SEK 51m
Dec 31 2022	SEK 18m	SEK 5m	-SEK 68m
Sep 30 2022	n/a	n/a	-SEK 72m
Jun 30 2022	n/a	n/a	-SEK 71m
Mar 31 2022	n/a	n/a	-SEK 82m
Dec 31 2021	SEK 6m	SEK 4m	-SEK 86m
Sep 30 2021	n/a	n/a	-SEK 88m
Jun 30 2021	n/a	n/a	-SEK 96m
Mar 31 2021	n/a	n/a	-SEK 92m
Dec 31 2020	SEK 11m	SEK 6m	-SEK 101m
Sep 30 2020	n/a	n/a	-SEK 115m
Jun 30 2020	n/a	n/a	-SEK 127m
Mar 31 2020	n/a	n/a	-SEK 151m
Dec 31 2019	SEK 8m	SEK 5m	-SEK 161m
Sep 30 2019	n/a	n/a	-SEK 166m
Jun 30 2019	n/a	n/a	-SEK 191m
Mar 31 2019	n/a	n/a	-SEK 182m
Dec 31 2018	SEK 6m	SEK 4m	-SEK 176m

Compensación vs. Mercado: La compensación total de Emil($USD1.38M) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD934.29K).

Compensación vs. Ingresos: La compensación de Emil ha sido consistente con los resultados de la empresa en el último año.

CEO

Emil Billbäck (54 yo)

6.7yrs

Permanencia

SEK 15,176,000

Compensación

Mr. Emil Billbäck serves as Director of Intervacc AB (publ) since May 15, 2024. He has been Chief Executive Officer at BONESUPPORT HOLDING AB (publ) since March 01, 2018. Mr. Billbäck is the Chief Executiv...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Emil Billbäck	Chief Executive Officer	6.7yrs	SEK 15.18m	0.33% SEK 81.0m
Håkan Johansson	Chief Financial Officer	6yrs	SEK 248.00k	0.084% SEK 20.4m
Michael Mortensen	Executive Vice President of Global R&D and Operations	2.9yrs	sin datos	sin datos
Annelie Vikner	Executive Vice President of Global Marketing	1.8yrs	sin datos	0.019% SEK 4.6m
Helena Brandt	Executive Vice President of Human Resources	7.1yrs	sin datos	0.0076% SEK 1.8m
Michael Diefenbeck	Executive VP of Medical & Clinical Affairs and Chief Medical Officer	7.6yrs	sin datos	0.14% SEK 33.1m
Fergus MacLeod	GM & Executive VP of Commercial Operations of EUROW	5yrs	sin datos	0.036% SEK 8.9m
Michael Roth	GM & Executive VP of Commercial Operations of North America	4.4yrs	sin datos	0.030% SEK 7.4m
Anna Stegmark	Executive Vice President of Quality Management & Regulatory Affairs	less than a year	sin datos	sin datos

5.0yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BONEX es experimentado (5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Björn Odlander	Director	14.8yrs	SEK 302.00k	sin datos
Lennart Johansson	Independent Chairman of the Board	7.8yrs	SEK 2.94m	0.25% SEK 61.9m
Sven Bjorklund	Independent Director	7.9yrs	SEK 253.00k	sin datos
Christine Rankin	Independent Director	2.5yrs	SEK 756.00k	0.0036% SEK 864.8k
Mary O'Connor	Independent Director	2.5yrs	SEK 515.00k	0.039% SEK 9.5m

7.8yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de BONEX se considera experimentada (7.8 años de antigüedad promedio).

Bonesupport Holding Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insider recently sold kr10m worth of stock

Insider recently sold kr1.7m worth of stock

Insider recently sold kr690k worth of stock

Chief Executive Officer recently sold kr18m worth of stock

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Key Executive recently sold kr3.6m worth of stock

Recent updates

Insider recently sold kr10m worth of stock

Price target increased by 12% to kr362

Insider recently sold kr1.7m worth of stock

Now 21% undervalued

Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB.

Insider recently sold kr690k worth of stock

Bonesupport Holding AB (publ) to Report Q2, 2025 Results on Jul 15, 2025

Third quarter 2024 earnings released: EPS: kr0.47 (vs kr3.52 in 3Q 2023)

Now 22% undervalued

Price target increased by 8.6% to kr323

Consensus EPS estimates fall by 12%, revenue upgraded

Chief Executive Officer recently sold kr18m worth of stock

Second quarter 2024 earnings released: EPS: kr0.42 (vs kr0.08 in 2Q 2023)

Consensus EPS estimates fall by 14%

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Key Executive recently sold kr3.6m worth of stock

Insider recently sold kr478k worth of stock

First quarter 2024 earnings released

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to kr293

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded

Independent Director recently bought kr1.0m worth of stock

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Price target increased by 11% to kr179

Third quarter 2023 earnings released

Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection

Independent Director recently bought kr1.1m worth of stock

Insider recently bought kr426k worth of stock

Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)

BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures

Insider recently sold kr701k worth of stock

Forecast breakeven date moved forward to 2023

Chief Executive Officer recently sold kr15m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold kr1.4m worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Price target increased by 17% to kr142

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

Director recently bought kr203k worth of stock

No independent directors

Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Bonesupport's CERAMENT G Used in First U.S. Patient Cases

Forecast to breakeven in 2023

An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million.

Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G

Consensus forecasts updated

Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)

Insider recently bought kr101k worth of stock

Forecast breakeven date moved forward to 2023

Price target increased to kr91.00

BONESUPPORT Receives Market Authorization for CERAMENT G in the US

Forecast breakeven date pushed back to 2024

Chairman of the Board recently bought kr1.2m worth of stock

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insider recently bought kr182k worth of stock